Home/RS Oncology/Jarrett Duncan

JD

Jarrett Duncan

Chief Executive Officer

Therapeutic Areas

RS Oncology Pipeline

Drug	Indication	Phase
RSO-021	Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Non-Small Cell Lung Cancer	Phase 2

Leadership Team at RS Oncology

Brian Cunniff, PhD

Chief Science Officer

Nichole Pfeiffer Hicks

Patient Advocacy Liaison & Strategic Partnerships

Christine Linnehan-Sununu

Communications & Branding

Dean Fennell, MRCP, FRCP

Clinical Advisory Board Director

View full RS Oncology profile